Myeloablative therapy and bone marrow rescue in advanced neuroblastoma. Report from the Italian Bone Marrow Transplant Registry

A. Garaventa, R. Rondelli, E. Lanino, S. Dallorso, G. Dini, F. Bonetti, A. Arrighini, N. Santoro, F. Rossetti, R. Miniero, M. Andolina, A. Amici, P. Indolfi, M. Lo Curto, C. Favre, P. Paolucci, A. Pession, B. De Bernardi

Research output: Contribution to journalArticle

Abstract

This study reports a large cooperative experience in myeloablative therapy and bone marrow rescue undertaken to define better the outcome of children with disseminated neuroblastoma after megatherapy. Between 1984 and 1993, 135 children underwent myeloablative therapy with bone marrow transplantation (BMT) in nine Italian Centres. One hundred and seventeen children received unpurged autologous BMT, five allogeneic BMT and 13 peripheral blood progenitor cells as rescue. Of these 135 children, 57 were in 1st CR, 11 in 2nd or subsequent CR, 42 in 1st PR, and 25 had more advanced disease. Twelve children (9%) died of toxicity, 86 relapsed or progressed at 1-68 months (median 7 months) and 80 of these subsequently died of progressive disease. Forty-three children are still alive with 37 in continuous remission at a median of 65 months (30-123 months) after BMT. Overall and disease-free survival at 8 years are 28.5% (s.e. 4.3) and 26% (s.e. 4), respectively. Disease-free survival is 34.6% (se. 6.7) for the patients grafted in 1st complete remission, 23.6% (se. 6.6) for patients grafted in 1st partial remission, 36.4% (s.e. 14.5) for patients grafted in 2nd or subsequent CR, and 8% (5.4) for patients with advanced disease. We conclude these data confirm that early toxicity of myeloablative therapy is manageable and that myeloablative therapy with bone marrow rescue may contribute to an improved long-term survival of children with disseminated neuroblastoma but the objective of cure of all patients remains distant.

Original languageEnglish
Pages (from-to)125-130
Number of pages6
JournalBone Marrow Transplantation
Volume18
Issue number1
Publication statusPublished - Jul 1996

Fingerprint

Neuroblastoma
Registries
Bone Marrow
Transplants
Bone Marrow Transplantation
Therapeutics
Disease-Free Survival
Autologous Transplantation
Homologous Transplantation
Blood Cells
Stem Cells
Survival

Keywords

  • Bone marrow graft
  • Megatherapy
  • Neuroblastoma

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Myeloablative therapy and bone marrow rescue in advanced neuroblastoma. Report from the Italian Bone Marrow Transplant Registry. / Garaventa, A.; Rondelli, R.; Lanino, E.; Dallorso, S.; Dini, G.; Bonetti, F.; Arrighini, A.; Santoro, N.; Rossetti, F.; Miniero, R.; Andolina, M.; Amici, A.; Indolfi, P.; Lo Curto, M.; Favre, C.; Paolucci, P.; Pession, A.; De Bernardi, B.

In: Bone Marrow Transplantation, Vol. 18, No. 1, 07.1996, p. 125-130.

Research output: Contribution to journalArticle

Garaventa, A, Rondelli, R, Lanino, E, Dallorso, S, Dini, G, Bonetti, F, Arrighini, A, Santoro, N, Rossetti, F, Miniero, R, Andolina, M, Amici, A, Indolfi, P, Lo Curto, M, Favre, C, Paolucci, P, Pession, A & De Bernardi, B 1996, 'Myeloablative therapy and bone marrow rescue in advanced neuroblastoma. Report from the Italian Bone Marrow Transplant Registry', Bone Marrow Transplantation, vol. 18, no. 1, pp. 125-130.
Garaventa, A. ; Rondelli, R. ; Lanino, E. ; Dallorso, S. ; Dini, G. ; Bonetti, F. ; Arrighini, A. ; Santoro, N. ; Rossetti, F. ; Miniero, R. ; Andolina, M. ; Amici, A. ; Indolfi, P. ; Lo Curto, M. ; Favre, C. ; Paolucci, P. ; Pession, A. ; De Bernardi, B. / Myeloablative therapy and bone marrow rescue in advanced neuroblastoma. Report from the Italian Bone Marrow Transplant Registry. In: Bone Marrow Transplantation. 1996 ; Vol. 18, No. 1. pp. 125-130.
@article{4fec04179cfe48409aa29ea198a2e588,
title = "Myeloablative therapy and bone marrow rescue in advanced neuroblastoma. Report from the Italian Bone Marrow Transplant Registry",
abstract = "This study reports a large cooperative experience in myeloablative therapy and bone marrow rescue undertaken to define better the outcome of children with disseminated neuroblastoma after megatherapy. Between 1984 and 1993, 135 children underwent myeloablative therapy with bone marrow transplantation (BMT) in nine Italian Centres. One hundred and seventeen children received unpurged autologous BMT, five allogeneic BMT and 13 peripheral blood progenitor cells as rescue. Of these 135 children, 57 were in 1st CR, 11 in 2nd or subsequent CR, 42 in 1st PR, and 25 had more advanced disease. Twelve children (9{\%}) died of toxicity, 86 relapsed or progressed at 1-68 months (median 7 months) and 80 of these subsequently died of progressive disease. Forty-three children are still alive with 37 in continuous remission at a median of 65 months (30-123 months) after BMT. Overall and disease-free survival at 8 years are 28.5{\%} (s.e. 4.3) and 26{\%} (s.e. 4), respectively. Disease-free survival is 34.6{\%} (se. 6.7) for the patients grafted in 1st complete remission, 23.6{\%} (se. 6.6) for patients grafted in 1st partial remission, 36.4{\%} (s.e. 14.5) for patients grafted in 2nd or subsequent CR, and 8{\%} (5.4) for patients with advanced disease. We conclude these data confirm that early toxicity of myeloablative therapy is manageable and that myeloablative therapy with bone marrow rescue may contribute to an improved long-term survival of children with disseminated neuroblastoma but the objective of cure of all patients remains distant.",
keywords = "Bone marrow graft, Megatherapy, Neuroblastoma",
author = "A. Garaventa and R. Rondelli and E. Lanino and S. Dallorso and G. Dini and F. Bonetti and A. Arrighini and N. Santoro and F. Rossetti and R. Miniero and M. Andolina and A. Amici and P. Indolfi and {Lo Curto}, M. and C. Favre and P. Paolucci and A. Pession and {De Bernardi}, B.",
year = "1996",
month = "7",
language = "English",
volume = "18",
pages = "125--130",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Myeloablative therapy and bone marrow rescue in advanced neuroblastoma. Report from the Italian Bone Marrow Transplant Registry

AU - Garaventa, A.

AU - Rondelli, R.

AU - Lanino, E.

AU - Dallorso, S.

AU - Dini, G.

AU - Bonetti, F.

AU - Arrighini, A.

AU - Santoro, N.

AU - Rossetti, F.

AU - Miniero, R.

AU - Andolina, M.

AU - Amici, A.

AU - Indolfi, P.

AU - Lo Curto, M.

AU - Favre, C.

AU - Paolucci, P.

AU - Pession, A.

AU - De Bernardi, B.

PY - 1996/7

Y1 - 1996/7

N2 - This study reports a large cooperative experience in myeloablative therapy and bone marrow rescue undertaken to define better the outcome of children with disseminated neuroblastoma after megatherapy. Between 1984 and 1993, 135 children underwent myeloablative therapy with bone marrow transplantation (BMT) in nine Italian Centres. One hundred and seventeen children received unpurged autologous BMT, five allogeneic BMT and 13 peripheral blood progenitor cells as rescue. Of these 135 children, 57 were in 1st CR, 11 in 2nd or subsequent CR, 42 in 1st PR, and 25 had more advanced disease. Twelve children (9%) died of toxicity, 86 relapsed or progressed at 1-68 months (median 7 months) and 80 of these subsequently died of progressive disease. Forty-three children are still alive with 37 in continuous remission at a median of 65 months (30-123 months) after BMT. Overall and disease-free survival at 8 years are 28.5% (s.e. 4.3) and 26% (s.e. 4), respectively. Disease-free survival is 34.6% (se. 6.7) for the patients grafted in 1st complete remission, 23.6% (se. 6.6) for patients grafted in 1st partial remission, 36.4% (s.e. 14.5) for patients grafted in 2nd or subsequent CR, and 8% (5.4) for patients with advanced disease. We conclude these data confirm that early toxicity of myeloablative therapy is manageable and that myeloablative therapy with bone marrow rescue may contribute to an improved long-term survival of children with disseminated neuroblastoma but the objective of cure of all patients remains distant.

AB - This study reports a large cooperative experience in myeloablative therapy and bone marrow rescue undertaken to define better the outcome of children with disseminated neuroblastoma after megatherapy. Between 1984 and 1993, 135 children underwent myeloablative therapy with bone marrow transplantation (BMT) in nine Italian Centres. One hundred and seventeen children received unpurged autologous BMT, five allogeneic BMT and 13 peripheral blood progenitor cells as rescue. Of these 135 children, 57 were in 1st CR, 11 in 2nd or subsequent CR, 42 in 1st PR, and 25 had more advanced disease. Twelve children (9%) died of toxicity, 86 relapsed or progressed at 1-68 months (median 7 months) and 80 of these subsequently died of progressive disease. Forty-three children are still alive with 37 in continuous remission at a median of 65 months (30-123 months) after BMT. Overall and disease-free survival at 8 years are 28.5% (s.e. 4.3) and 26% (s.e. 4), respectively. Disease-free survival is 34.6% (se. 6.7) for the patients grafted in 1st complete remission, 23.6% (se. 6.6) for patients grafted in 1st partial remission, 36.4% (s.e. 14.5) for patients grafted in 2nd or subsequent CR, and 8% (5.4) for patients with advanced disease. We conclude these data confirm that early toxicity of myeloablative therapy is manageable and that myeloablative therapy with bone marrow rescue may contribute to an improved long-term survival of children with disseminated neuroblastoma but the objective of cure of all patients remains distant.

KW - Bone marrow graft

KW - Megatherapy

KW - Neuroblastoma

UR - http://www.scopus.com/inward/record.url?scp=9544255700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9544255700&partnerID=8YFLogxK

M3 - Article

C2 - 8832005

AN - SCOPUS:9544255700

VL - 18

SP - 125

EP - 130

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 1

ER -